Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26888
DepoFoam is a technology by which drugs taken by injection are formulated to release over an extended period of time.
IPSCIO Record ID: 314332
Licensee desires to obtain, and Licensor is willing to grant, an exclusive, worldwide license to the proprietary DepoFoamÂ® delivery system in order to develop and commercialize formulations of Liraglutide.
Formulation Intellectual Property means all Know-How arising from activities performed under this Agreement regarding formulations of Liraglutide with DepoFoam and/or methods or processes for making or using such formulations.
Liraglutide means Licensees proprietary, human Glucagon-Like Peptide-1 (GLP-1} analogue.
Liraglutide is a medication used to treat diabetes mellitus type 2 and obesity.
IPSCIO Record ID: 27061
The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.
1) Directly compressible sustained release excipient.
2) Sustained release excipient and tablet formulation.
3) Compressible sustained release solid dosage forms.
4) EPO Application No. 89309518.2; filed September 19, 1989.
5) Australian Patent Application No. 43057/89
6) Japanese Patent Application No. 1-510135
7) Irish Patent Application No. 2968/89
8) Canadian Patent Application No. 611,700
9) Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.
10) 2 U.S. Applications on Bi-modal release.